Loading...
XNASSBFM
Market cap5mUSD
Dec 23, Last price  
3.00USD
1D
7.91%
1Q
-0.99%
Jan 2017
-99.97%
IPO
-100.00%
Name

Sunshine Biopharma Inc

Chart & Performance

D1W1MN
XNAS:SBFM chart
P/E
P/S
0.25
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
-4.40%
Rev. gr., 5y
121.96%
Revenues
24m
+454.42%
000000001,70800447,20021,12171,410228,4264,345,60324,092,787
Net income
-5m
L-83.15%
-13,122-31,1050-537,382-556,202-707,952-2,491,483-1,934,210-1,652,908-3,496,687-1,040,236-2,156,155-1,461,440-897,683-12,765,265-26,744,440-4,506,044
CFO
-9m
L+67.20%
-3,122-27,533-10,225-348,325-297,299-393,054-564,398-538,595-867,644-314,182-543,520-512,806-495,798-657,299-1,829,128-5,248,358-8,775,111
Earnings
Mar 26, 2025

Profile

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
IPO date
Aug 15, 2008
Employees
46
Domiciled in
CA
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
24,093
454.42%
4,346
1,802.41%
228
219.88%
Cost of revenue
28,439
12,939
2,656
Unusual Expense (Income)
NOPBT
(4,346)
(8,594)
(2,427)
NOPBT Margin
Operating Taxes
395
233
329
Tax Rate
NOPAT
(4,742)
(8,827)
(2,756)
Net income
(4,506)
-83.15%
(26,744)
109.51%
(12,765)
1,322.02%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,548
30,268
BB yield
-53.71%
-311.55%
Debt
Debt current
119
3,632
Long-term debt
1,197
1,284
1,900
Deferred revenue
(43)
Other long-term liabilities
43
(1,900)
Net debt
(14,977)
(18,540)
(145)
Cash flow
Cash from operating activities
(8,775)
(5,248)
(1,829)
CAPEX
(82)
(305)
Cash from investing activities
(656)
(14,619)
Cash from financing activities
3,426
39,465
2,905
FCF
(5,877)
(12,102)
(2,803)
Balance
Cash
16,292
21,826
2,045
Long term investments
1,630
Excess cash
15,088
23,239
2,034
Stockholders' equity
(63,181)
(59,214)
(32,576)
Invested Capital
85,046
84,743
34,687
ROIC
ROCE
EV
Common stock shares outstanding
12
8
1
Price
543.00
-57.58%
1,280.00
-81.75%
7,014.00
272.29%
Market cap
6,606
-32.01%
9,715
6.06%
9,160
461.45%
EV
(8,370)
(8,824)
9,115
EBITDA
(4,197)
(8,568)
(2,415)
EV/EBITDA
1.99
1.03
Interest
137
39
329
Interest/NOPBT